{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/110830"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/110830","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Development of therapeutic agents for myotonic dystrophy type 1","abstract":"Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder which is caused by a dominantly inherited (CTG·CAG) repeat expansion in the 3’-UTR of the Dystrophia Myotonica Protein Kinase (DMPK) gene on chromosome 19. The genetic basis of DM1 is that DMPK is transcribed into an mRNA transcript with an expanded CUG repeat, r(CUG)exp, which can form hairpin secondary structures. These hairpin structures sequester the muscleblind-like (MBNL) family of proteins. MBNL proteins are responsible for post-transcriptional splicing and polyadenylation site regulation. The sequestration of MBNL proteins prevents them from performing their proper function, leading to hundreds of splicing defects. DM1 therapeutic efforts have been focused on inhibiting the interaction between r(CUG)exp and MBNL1 proteins, because it is estimated that over 80% of DM1 splicing defects are related to MBNL1 sequestration. This dissertation focuses on the development of rationally designed small molecules that can function as potential therapeutic agents, including their synthesis and studies of their biological activity. The background of DM1 with a focus on its molecular mechanism and various therapeutic strategies are reviewed in Chapter 1. Chapter 2 reports a series of multitargeting oligomeric ligands that have been developed to serve as both drug molecules and as antisense delivery vehicles for DM1. As a result of multivalency, the longer oligomers bound to the target DNA and RNA with nanomolar affinities in vitro and exhibited improved disease outcomes in DM1 model cell culture and DM1 patient myotubes. In addition, the oligomer can form polyplexes with a locked nucleic acid (LNA) CAG16 gapmer, facilitating its cell uptake in both HeLa cells and DM1 patient myotubes, with a resulting decrease in the level of toxic r(CUG)exp significantly. RNA-seq analysis indicated that the oligomeric ligand and its polyplex can rescue DM1 associated splicing defects and gene expression changes transcriptome-wide in DM1 patient myotubes. Chapter 3 discusses a rationally designed minor groove binder for DM1 as a potential therapeutic agent. The ligand contains triaminotriazine as a selective recognition moiety for T-T and U-U mismatches, and a thiazole peptidomimetic linker as a minor groove binder. This ligand is shown to rescue DM1 related defects in vitro and in DM1 model cell culture, including decreasing toxic cellular r(CUG)exp level, foci dispersion, and Insulin Receptor (IR) pre-mRNA mis-splicing rescue.","abstract_html":"Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder which is caused by a dominantly inherited (CTG·CAG) repeat expansion in the 3’-UTR of the Dystrophia Myotonica Protein Kinase (DMPK) gene on chromosome 19. The genetic basis of DM1 is that DMPK is transcribed into an mRNA transcript with an expanded CUG repeat, r(CUG)exp, which can form hairpin secondary structures. These hairpin structures sequester the muscleblind-like (MBNL) family of proteins. MBNL proteins are responsible for post-transcriptional splicing and polyadenylation site regulation. The sequestration of MBNL proteins prevents them from performing their proper function, leading to hundreds of splicing defects. DM1 therapeutic efforts have been focused on inhibiting the interaction between r(CUG)exp and MBNL1 proteins, because it is estimated that over 80% of DM1 splicing defects are related to MBNL1 sequestration. This dissertation focuses on the development of rationally designed small molecules that can function as potential therapeutic agents, including their synthesis and studies of their biological activity. The background of DM1 with a focus on its molecular mechanism and various therapeutic strategies are reviewed in Chapter 1. Chapter 2 reports a series of multitargeting oligomeric ligands that have been developed to serve as both drug molecules and as antisense delivery vehicles for DM1. As a result of multivalency, the longer oligomers bound to the target DNA and RNA with nanomolar affinities in vitro and exhibited improved disease outcomes in DM1 model cell culture and DM1 patient myotubes. In addition, the oligomer can form polyplexes with a locked nucleic acid (LNA) CAG16 gapmer, facilitating its cell uptake in both HeLa cells and DM1 patient myotubes, with a resulting decrease in the level of toxic r(CUG)exp significantly. RNA-seq analysis indicated that the oligomeric ligand and its polyplex can rescue DM1 associated splicing defects and gene expression changes transcriptome-wide in DM1 patient myotubes. Chapter 3 discusses a rationally designed minor groove binder for DM1 as a potential therapeutic agent. The ligand contains triaminotriazine as a selective recognition moiety for T-T and U-U mismatches, and a thiazole peptidomimetic linker as a minor groove binder. This ligand is shown to rescue DM1 related defects in vitro and in DM1 model cell culture, including decreasing toxic cellular r(CUG)exp level, foci dispersion, and Insulin Receptor (IR) pre-mRNA mis-splicing rescue.","abstract_has_math":false,"creators":["Li, Ke"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":["Zimmerman, Steven C","Chan, Jefferson","van der Donk, Wilfred","Lu, Yi"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-09-17T04:04:31Z","date_published":"2021-09-17T04:04:31Z","updated_at":"2026-07-22T22:24:52Z","subjects":["Myotonic Dystrophy","Therapeutic Agents"],"languages":["en"],"rights":["Copyright 2021 Ke Li"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/110830","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Zimmerman, Steven C","Chan, Jefferson","van der Donk, Wilfred","Lu, Yi"]},{"key":"dc:creator","label":"Author","values":["Li, Ke"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2021-09-17T04:04:31Z","2023-09-17T04:07:01Z","2021-04-19","2021-05"]},{"key":"dc:type","label":"Dc Type","values":["text","Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Myotonic Dystrophy","Therapeutic Agents"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2021 Ke Li"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/110830"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder which is caused by a dominantly inherited (CTG·CAG) repeat expansion in the 3’-UTR of the Dystrophia Myotonica Protein Kinase (DMPK) gene on chromosome 19. The genetic basis of DM1 is that DMPK is transcribed into an mRNA transcript with an expanded CUG repeat, r(CUG)exp, which can form hairpin secondary structures. These hairpin structures sequester the muscleblind-like (MBNL) family of proteins. MBNL proteins are responsible for post-transcriptional splicing and polyadenylation site regulation. The sequestration of MBNL proteins prevents them from performing their proper function, leading to hundreds of splicing defects. DM1 therapeutic efforts have been focused on inhibiting the interaction between r(CUG)exp and MBNL1 proteins, because it is estimated that over 80% of DM1 splicing defects are related to MBNL1 sequestration. This dissertation focuses on the development of rationally designed small molecules that can function as potential therapeutic agents, including their synthesis and studies of their biological activity. The background of DM1 with a focus on its molecular mechanism and various therapeutic strategies are reviewed in Chapter 1. Chapter 2 reports a series of multitargeting oligomeric ligands that have been developed to serve as both drug molecules and as antisense delivery vehicles for DM1. As a result of multivalency, the longer oligomers bound to the target DNA and RNA with nanomolar affinities in vitro and exhibited improved disease outcomes in DM1 model cell culture and DM1 patient myotubes. In addition, the oligomer can form polyplexes with a locked nucleic acid (LNA) CAG16 gapmer, facilitating its cell uptake in both HeLa cells and DM1 patient myotubes, with a resulting decrease in the level of toxic r(CUG)exp significantly. RNA-seq analysis indicated that the oligomeric ligand and its polyplex can rescue DM1 associated splicing defects and gene expression changes transcriptome-wide in DM1 patient myotubes. Chapter 3 discusses a rationally designed minor groove binder for DM1 as a potential therapeutic agent. The ligand contains triaminotriazine as a selective recognition moiety for T-T and U-U mismatches, and a thiazole peptidomimetic linker as a minor groove binder. This ligand is shown to rescue DM1 related defects in vitro and in DM1 model cell culture, including decreasing toxic cellular r(CUG)exp level, foci dispersion, and Insulin Receptor (IR) pre-mRNA mis-splicing rescue.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2023-05-01","The student, Ke Li, accepted the attached license on 2021-04-19 at 08:47.","The student, Ke Li, submitted this Dissertation for approval on 2021-04-19 at 08:48.","This Dissertation was approved for publication on 2021-04-19 at 15:42.","DSpace SAF Submission Ingestion Package generated from Vireo submission #16397 on 2021-09-16 at 20:10:32","Made available in DSpace on 2021-09-17T04:04:31Z (GMT). No. of bitstreams: 2 LI-DISSERTATION-2021.pdf: 5244083 bytes, checksum: 6811723368453a72f6d283ae161b7427 (MD5) LICENSE.txt: 4202 bytes, checksum: f7d9b96c5be06d3fda7c465fc1b213a7 (MD5) Previous issue date: 2021-04-19","Embargo set by: Seth Robbins for item 118675 Lift date: 2023-09-17T04:04:53Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 118675 Lift date: 2023-09-17T04:07:01Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Development of therapeutic agents for myotonic dystrophy type 1"]}]}],"canonical_facts":{"dc:contributor":["Zimmerman, Steven C","Chan, Jefferson","van der Donk, Wilfred","Lu, Yi"],"dc:creator":["Li, Ke"],"dc:date":["2021-09-17T04:04:31Z","2023-09-17T04:07:01Z","2021-04-19","2021-05"],"dc:description":["Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder which is caused by a dominantly inherited (CTG·CAG) repeat expansion in the 3’-UTR of the Dystrophia Myotonica Protein Kinase (DMPK) gene on chromosome 19. The genetic basis of DM1 is that DMPK is transcribed into an mRNA transcript with an expanded CUG repeat, r(CUG)exp, which can form hairpin secondary structures. These hairpin structures sequester the muscleblind-like (MBNL) family of proteins. MBNL proteins are responsible for post-transcriptional splicing and polyadenylation site regulation. The sequestration of MBNL proteins prevents them from performing their proper function, leading to hundreds of splicing defects. DM1 therapeutic efforts have been focused on inhibiting the interaction between r(CUG)exp and MBNL1 proteins, because it is estimated that over 80% of DM1 splicing defects are related to MBNL1 sequestration. This dissertation focuses on the development of rationally designed small molecules that can function as potential therapeutic agents, including their synthesis and studies of their biological activity. The background of DM1 with a focus on its molecular mechanism and various therapeutic strategies are reviewed in Chapter 1. Chapter 2 reports a series of multitargeting oligomeric ligands that have been developed to serve as both drug molecules and as antisense delivery vehicles for DM1. As a result of multivalency, the longer oligomers bound to the target DNA and RNA with nanomolar affinities in vitro and exhibited improved disease outcomes in DM1 model cell culture and DM1 patient myotubes. In addition, the oligomer can form polyplexes with a locked nucleic acid (LNA) CAG16 gapmer, facilitating its cell uptake in both HeLa cells and DM1 patient myotubes, with a resulting decrease in the level of toxic r(CUG)exp significantly. RNA-seq analysis indicated that the oligomeric ligand and its polyplex can rescue DM1 associated splicing defects and gene expression changes transcriptome-wide in DM1 patient myotubes. Chapter 3 discusses a rationally designed minor groove binder for DM1 as a potential therapeutic agent. The ligand contains triaminotriazine as a selective recognition moiety for T-T and U-U mismatches, and a thiazole peptidomimetic linker as a minor groove binder. This ligand is shown to rescue DM1 related defects in vitro and in DM1 model cell culture, including decreasing toxic cellular r(CUG)exp level, foci dispersion, and Insulin Receptor (IR) pre-mRNA mis-splicing rescue.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2023-05-01","The student, Ke Li, accepted the attached license on 2021-04-19 at 08:47.","The student, Ke Li, submitted this Dissertation for approval on 2021-04-19 at 08:48.","This Dissertation was approved for publication on 2021-04-19 at 15:42.","DSpace SAF Submission Ingestion Package generated from Vireo submission #16397 on 2021-09-16 at 20:10:32","Made available in DSpace on 2021-09-17T04:04:31Z (GMT). No. of bitstreams: 2 LI-DISSERTATION-2021.pdf: 5244083 bytes, checksum: 6811723368453a72f6d283ae161b7427 (MD5) LICENSE.txt: 4202 bytes, checksum: f7d9b96c5be06d3fda7c465fc1b213a7 (MD5) Previous issue date: 2021-04-19","Embargo set by: Seth Robbins for item 118675 Lift date: 2023-09-17T04:04:53Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 118675 Lift date: 2023-09-17T04:07:01Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited"],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/110830"],"dc:language":["en"],"dc:rights":["Copyright 2021 Ke Li"],"dc:subject":["Myotonic Dystrophy","Therapeutic Agents"],"dc:title":["Development of therapeutic agents for myotonic dystrophy type 1"],"dc:type":["text","Thesis"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:52Z"}